Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis

Trial Profile

An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms AURONA™
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2018 According to an Aurinia Pharmaceuticals media release, the company had submitted Investigational New Drug application to the FDA in Q1 2018 and received agreement from the FDA with regards to the guidance we provided on this study.
    • 25 Jun 2018 Status changed from planning to recruiting, according to an Aurinia Pharmaceuticals media release.
    • 10 May 2018 According to an Aurinia Pharmaceuticals media release, this trial is expected to initiate in June 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top